A basket trial of AZEDRA (iobenguane I 131) for the treatment of patients with unresectable or metastatic neuroendocrine tumors (NETs) who are MIBG avid

Status: Planning

Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

09 Aug 2019 Planned number of patients changed from 120 to 150, according to an Progenics Pharmaceuticals media release.
25 Jun 2019 New trial record
20 Jun 2019 According to a Progenics Pharmaceuticals media release, the company plans to initiate the study by the end of 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com